{"disease":{"id":"erythrodermic-psoriasis","name":"Erythrodermic psoriasis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":17,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"risankizumab","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Skyrizi","generic_name":"RISANKIZUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Interleukin-23 subunit alpha","drug_class":"Interleukin-23 Antagonist [EPC]","quality_score":10,"revenue":"8600","mechanism":"Skyrizi works by blocking the interleukin-23 protein, which plays a key role in inflammation and immune response."},{"drug_id":"chembl-chembl1201581","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remicade","generic_name":"INFLIXIMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":73,"revenue":"4200","mechanism":"Remicade works by binding to and neutralizing tumor necrosis factor, a protein that promotes inflammation and tissue damage."},{"drug_id":"ixekizumab","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taltz","generic_name":"ixekizumab","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Interleukin 17A (IL-17A) cytokine","drug_class":"Interleukin-17A antagonist","quality_score":82,"revenue":"2700","mechanism":"Humanized IgG4 monoclonal antibody that selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor."},{"drug_id":"certolizumab-pegol","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cimzia","generic_name":"CERTOLIZUMAB PEGOL","company_name":"UCB","drug_phase":"marketed","molecular_target":"TNFα","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":68,"revenue":"1600","mechanism":"Certolizumab pegol binds to and neutralizes human TNFα, reducing inflammation without causing antibody-dependent cell-mediated cytotoxicity."},{"drug_id":"bimekizumab","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bimzelx","generic_name":"BIMEKIZUMAB","company_name":"Ucb Japan Co., Ltd.","drug_phase":"marketed","molecular_target":"Interleukin-17A","drug_class":"","quality_score":55,"revenue":"1200","mechanism":"Bimzelx works by binding to interleukin-17A, a protein that promotes inflammation, to reduce symptoms of psoriasis."},{"drug_id":"spesolimab","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spevigo","generic_name":"SPESOLIMAB","company_name":"Boehringer Ingelheim Pharmaceuticals Inc","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor-like 2","drug_class":"Interleukin-36 Receptor Antagonist [EPC]","quality_score":62,"revenue":"300","mechanism":"Spevigo works by blocking the interleukin-36 receptor, which plays a key role in the development of psoriasis symptoms."},{"drug_id":"deucravacitinib","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sotyktu","generic_name":"DEUCRAVACITINIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Non-receptor tyrosine-protein kinase TYK2","drug_class":"Tyrosine Kinase 2 Inhibitor [EPC]","quality_score":69,"revenue":"291","mechanism":"Sotyktu works by blocking the TYK2 enzyme, which is involved in the inflammatory response and contributes to the development of psoriasis."},{"drug_id":"spesolimab-sbzo","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SPEVIGO","generic_name":"SPESOLIMAB-SBZO","company_name":"BOEHRINGER INGELHEIM PHARMACEUTICALS INC","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor-like 2","drug_class":"Interleukin-36 Receptor Antagonist [EPC]","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"methotrexate","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trexall","generic_name":"methotrexate","company_name":"Generic (originally Lederle Laboratories)","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"Antifolate, DMARD","quality_score":55,"revenue":null,"mechanism":"Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune)."},{"drug_id":"methotrexat","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methotrexat","company_name":"Biocad","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cimzia","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cimzia","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"infliximab","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remicade","generic_name":"infliximab","company_name":"Johnson & Johnson","drug_phase":"discontinued","molecular_target":"TNFα","drug_class":"Monoclonal antibody","quality_score":43,"revenue":null,"mechanism":"Infliximab binds to TNFα, blocking its interaction with receptors, reducing inflammation and immune responses."},{"drug_id":"remicade","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Remicade","company_name":"Shanghai Biomabs Pharmaceutical Co., Ltd.","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"inflectra","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remicade","generic_name":"Infliximab-Dyyb","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor alpha (TNFα)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Infliximab-dyyb neutralizes TNFα by binding with high affinity to soluble and transmembrane forms, inhibiting receptor binding."},{"drug_id":"infliximab-qbtx","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"IXIFI","generic_name":"INFLIXIMAB-QBTX","company_name":"PFIZER INC","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"taltz","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taltz","company_name":"Yale University","drug_phase":"marketed","molecular_target":"Interleukin-17A","drug_class":"","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"bimekizumab-bkzx","indication_name":"Erythrodermic psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BIMZELX","generic_name":"BIMEKIZUMAB-BKZX","company_name":"UCB INC","drug_phase":"marketed","molecular_target":"Interleukin-17A, Interleukin-17F, Interleukin-17AF","drug_class":"","quality_score":42,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":17,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03051217","title":"A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT06801028","title":"Efficacy of Injection Sekucinumab in Erythrodermic Psoriasis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Jinnah Postgraduate Medical Centre","has_results":false},{"nct_id":"NCT06295692","title":"A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":19,"lead_sponsor_name":"Janssen Pharmaceutical K.K.","has_results":true},{"nct_id":"NCT06323356","title":"A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03942042","title":"A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT03885089","title":"Infliximab Biosimilar for Intravenous Drip Infusion 100 mg \"Pfizer\" Drug Use Investigation (Psoriasis)","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Pfizer","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}